DeCODE, based in Reykjavik, Iceland, has discovered genetic risk factors for dozens of diseases ranging from cardiovascular disease to cancer
"DeCODE Genetics has built a world-class capability in the study of the genetics of human disease. This capability will enhance our efforts to identify and validate human disease targets," Amgen CEO Robert Bradway said in a statement on Monday.
Amgen's board has approved the deal, which does not need regulatory approval. The transaction is expected to close before year's end.
Shares of Amgen, which is based in Thousand Oaks, Calif., slipped 12 cents to $88.20 in premarket trading. Its shares peaked for the past year at $89.95 in mid-October. They fell as low as $57.14 almost a year ago.
Among Amgen's products are the anemia drugs Aranesp and Epogen.
MORE HBJ HEADLINES
Hotel industry supplier Electric Mirror to expand in Everett Facebook ready to test giant drone for Internet service Economy up 2.3%; 1st quarter revised higher Our finance industry has grown too large Procter & Gamble sales dip on softer volume Briefs: Port of Everett awards $15,000 to support tourism
Our new comment system is not supported in IE 7. Please upgrade your browser here.